Brokerage Firm Rating Update on Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN) : 2 brokerage houses believe that Qiagen N.V. (QGEN) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 7 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Qiagen N.V. (QGEN). Zacks Investment Research suggests a Buy with a rank of 2. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock.The median of all the 11 Wall Street Analysts endorse the stock as a Hold with a rating of 2.59.

Qiagen N.V. (QGEN) stock is expected to deviate a maximum of $1.93 from the average target price of $25.81 for the short term period. 8 Street Experts have initiated coverage on the stock with the most promising target being $30 and the most muted being $24.


Company shares have received an average consensus rating of Hold for the current week Also, HSBC upgrades its view on Qiagen N.V. (NASDAQ:QGEN) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Hold. The rating by the firm was issued on August 1, 2016.

Qiagen N.V. (NASDAQ:QGEN): stock was range-bound between the intraday low of $26.87 and the intraday high of $27.08 after having opened at $27.08 on Wednesdays session. The stock finally closed in the red at $27.08, a loss of -0.07%. The stock remained in the red for the whole trading day. The total traded volume was 645,683 shares. The stock failed to cross $27.08 in Wednesdays trading. The stocks closing price on Thursday was $26.96.

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.